Varenicline Kit
Product Images NDC 27241-187

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 27241-187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0.5mg (Varenicline 05mg)

Label for Varenicline Tablets 0.5 mg film-coated oral tablets from Ajanta Pharma USA Inc. The label states a package of 56 tablets, includes storage instructions, dosage details, and pharmacist dispensing information. It also features a barcode and space for lot and expiration date.*

FDA Label Image

1mg (Varenicline 1mg)

Label for Varenicline Tablets 1 mg by Ajanta Pharma USA Inc. The label indicates 56 film-coated tablets per package and includes NDC 27241-174-56. Storage instructions and warnings about child resistance are present. The label also shows a barcode, lot and expiration placeholders, and manufacturer details noting the product is made in India.*

FDA Label Image

1mgback (Varenicline Continuing B)

This image shows four identical Varenicline Tablets labels, each for 1 mg film-coated tablets. The labels include dosage information, storage instructions (20°C to 25°C), and the marketer details, Ajanta Pharma USA Inc., Bridgewater, NJ, with tablets made in India. Each label also features an Rx symbol, a barcode, and the NDC 27241-174-11.*

FDA Label Image

1mgfront (Varenicline Continuing F)

An instructional adherence aid for Varenicline Tablets 1 mg, divided into four sections labeled 1 to 4, each representing a continuing week of dosing. Each section lists days 1 to 28 with separate morning and evening checkboxes for users to track tablet intake.*

FDA Label Image

Continuing-back (Varenicline Continuing Week B)

Varenicline Tablets packaging labels showing two strengths: 0.5 mg and 1 mg film-coated tablets. The 0.5 mg label is yellow-green, and the 1 mg labels are blue. Labels include dosage details, storage instructions, the labeler Ajanta Pharma USA Inc., and barcodes. The product is for oral use with Rx Only designation.*

FDA Label Image

Contnuing-front (Varenicline Continuing Week F)

This image shows a multi-week dosing calendar for Varenicline film-coated tablets in 0.5 mg and 1 mg strengths from Ajanta Pharma USA Inc. Each of the four sections corresponds to a weekly dose schedule, labeled Weeks 1 through 4, with designated spaces to mark morning and evening doses from Day 1 to Day 28. Instructions indicate taking one tablet morning and evening as per dose strength for each respective week.*

FDA Label Image

1mg-carton (Varenicline Continuingmonthbox)

Packaging label for Varenicline Tablets, a prescription oral film-coated tablet. The label notes a continuing month box containing 4 continuing weeks (1 mg x 56 tablets). The labeler is Ajanta Pharma USA Inc., located in Bridgewater, NJ. The box includes instructions for pharmacists to dispense an accompanying medication guide and storage, dosage, and warning information.*

FDA Label Image

Varenicline-figure3 (Varenicline Figure3)

A line graph showing continuous abstinence rates during nontreatment follow-up over weeks for Varenicline 1 mg tablets taken twice daily compared to placebo. The y-axis represents the percentage of continuous abstinent users, and the x-axis shows weeks of nontreatment follow-up. The Varenicline group maintains higher abstinence rates than the placebo group throughout the period.*

FDA Label Image

Starting-month-box (Varenicline Startingmonthbox)

Varenicline Tablets Starting Month Box packaging label for human prescription film-coated tablets. The carton contains 0.5 mg (11 tablets) for the starting week and 1 mg (42 tablets) for the continuing weeks, labeled by Ajanta Pharma USA Inc. The box includes directions and warnings with lot and expiration date fields.*

FDA Label Image

Varenicline-structure (Varenicline Structure)

Chemical structure of Varenicline, the active ingredient of this prescription drug. The diagram shows the molecular arrangement including core rings and attached functional groups relevant to Varenicline tartrate.*

FDA Label Image

Varenicline_figure1 (Varenicline Fig1)

A bar chart titled 'Continuous Abstinence, Weeks 9 through 12' comparing the percentage of abstinence for different treatments across five studies. Treatments include Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Placebo, Varenicline Flexible, Bupropion SR 150 mg BID, and Placebo. Each treatment bar has error bars indicating variability. The x-axis lists the treatments and studies, while the y-axis shows percentage abstinence from 0% to 60%.*

FDA Label Image

Varenicline-figure2 (Varenicline Figure2)

A bar chart titled 'Figure 2: Continuous Abstinence, Weeks 9 through 52' showing percentage data across four studies. Each study compares continuous abstinence rates for Varenicline tablets or flexible dosing, Bupropion SR 150 mg BID (in studies 4 and 5), and placebo, represented with different bar patterns, including error bars indicating variability. The y-axis shows percentage from 0% to 35%. The x-axis labels indicate study numbers and treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.